Lipha And Shaman In Diabetes Collaboration
Lipha of France, a subsidiary of the the German pharmaceutical company Merck KGaA, and Shaman Pharmaceuticals of the USA have entered into a five-year collaborative agreement to develop compounds identified by Shaman as potential treatments for diabetes.
This agreement follows a similar one announced by Shaman and Ono Pharmaceutical in May 1995. The agreement with Ono covers development and marketing of Shaman's antidiabetic drugs in Japan, South Korea, and Taiwan. The latest agreement with Lipha covers the rest of the world.
Under the terms of the Lipha agreement, in exchange for development and marketing rights to Shaman's antidiabetic drugs, Lipha will provide equity investments at a premium to the market price and collaborative research funding of $19.5 million over the five-year period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze